Oxyphenbutazone monohydrate
Grundinformationen
- CAS
7081-38-1- Standard-SMILES
CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O- InChIKey
CNDQSXOVEQXJOE-UHFFFAOYSA-N- Summenformel
- C19H22N2O4
- Durchschnittliche Molmasse
- 342,4 g/mol
- Monoisotopische Masse
- 342,15795719
Überblick
Oxyphenbutazone hydrate is a hydrate obtained by combining oxyphenbutazone with one molar equivalent of water. Commonly used to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. It has a role as an antimicrobial agent, a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic, an antineoplastic agent and a gout suppressant. It contains an oxyphenbutazone.
Namen und Bezeichner
- Bevorzugter Name
- Oxyphenbutazone monohydrate
- IUPAC
- 4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione;hydrate
- Englischer Name
- OXYPHENBUTAZONE HYDRATE
- Summenformel
- C19H22N2O4
- Molmasse
- 342.39
Namen und Synonyme
Oxyphenbutazone hydrate7081-38-1oxyphenbutazone monohydrate4-Butyl-1-(p-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione monohydrate3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-, monohydrateCHEBI:76259RefChem:1094101Oxyphenbutazone (monohydrate)4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione hydrate76576-51-7Tandearil (TN)4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione;hydrate
Weitere Namen anzeigen
OXYPHENYL BUTAZONE MONOHYDRATEOXYPHENBUTAZONE HYDRATE USP/EP/BPOxyphenbutazone (hydrate) - Bio-X ?Oxyphenbutazone DISCONTINUED (1 g)1-(4-hydroxyphenyl)-4-(3-oxobutyl)-2-phenylpyrazolidin-3-one:hydrate
Oxyphenbutazone (hydrate) - Bio-X trade mark4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione--water (1/1)4-butyl-1-(4-hydroxyphenyl)-2-phenyl-1,2-diazolidine-3,5-dione, hydrate3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1-(4-HYDROXYPHENYL)-2-PHENYL-, HYDRATE (1:1)UNII-H806S4B3NSOxyphenbutazone [USP:INN:BAN]SCHEMBL25854OXYPHENBUTAZONE [IARC]
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 61,9 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 4
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 25
- Formalladung
- 0
- Komplexität
- 454
Physikochemische Eigenschaften
- Schmelzpunkt
- 96 °; · 96°; mp 124-125°
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Gefahrenhinweise
Regulatory Information3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-, monohydrate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-, monohydrate: Environment tier I assessment
Sicherheitsdaten
- risk_code
- 22-36/38-40-42/43
- hazard_code
- Xn
- safety_code
- 22-26-36
Chemie und Industrie
Anwendungen
VerwendenAntiinflammatory; antirheumatic.
Anbieter8 Anbieter
艾吉析科技（上海）有限公司17717235263 · [email protected]
上海陶术生物科技股份有限公司13564774135 · [email protected]
成都标样生物科技有限公司028-81700200 13308200041 · [email protected]
TargetMol中国（陶术生物）4008200310 15002144251 · [email protected]
陕西西化化学工业有限公司18161915376 · [email protected]
DAYANG CHEM (HANGZHOU) CO.,LTD+86-88938639 +86-17705817739 · [email protected]
上海甄准生物科技有限公司18019219489 18901678489 · [email protected]
Dideu Industries Group Limited+86-29-81148696 +86-15129568250 · [email protected]
Ergänzende Hinweise
DefinitionChEBI: A hydrate obtained by combining oxyphenbutazone with one molar equivalent of water. Commonly used to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…